BioMarin Pharmaceuticals, Inc. (Nasdaq: BMRN) reported preliminary Q4 revenue of $146.9 million, versus consensus views looking for $143.6 million.

This article: 118 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE